Healthcare Global Enterprises Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Growth moderated, but by design: Q4 FY26 revenue grew 11.3% YoY, trailing the full-year 15%, as management intentionally pared low-margin business and the Middle East conflict dampened medical value travel. Both factors are being actively addressed.
• Margins expanded 70 bps for the year: FY26 EBITDA margin reached 18.5%, driven by operating leverage, better utilization, and cost discipline. Management sees another 100 bps improvement as achievable in FY27.
• Milann exit sharpens oncology focus: The fertility business, operating near break-even, was sold to Inviga Healthcare Fund for an enterprise value of ₹63 cr, freeing management bandwidth and capital for the core oncology network.
• Balance sheet reset complete: A ₹425 cr rights issue closed with strong demand, proceeds will reduce debt and interest costs, and the internal net debt-to-EBITDA ceiling is held at 2.5x.
• What to watch next quarter: Whether the low-margin business transition normalizes as guided, the pace of international patient volume recovery, and the ramp-up at the newly opened North Bangalore center.

Revenue Growth & the Intentional Moderation

• Conscious pruning of low-margin business: Management made a deliberate call to reduce lower-margin revenue across South, West, and East clusters, accepting a short-term growth headwind for a long-term benefit to margins, returns, and cash generation. This strategy has been applied with equal success in all clusters.
• Medical value travel hit by geopolitics: The Middle East conflict softened international patient inflows, particularly affecting the West and South clusters. A new Head of International Sales has been appointed to lead the recovery effort.
• Kenya was a bright spot: The international business grew 39% YoY in Q4 and 71% for the full year, supported by radiation oncology, PET services, and stronger patient inflows.
• Cluster-level dynamics: The West cluster, the largest at ~45% of FY26 revenue, grew ~14% for the year on strong Gujarat and Maharashtra inflows and Ahmedabad capacity expansion. The East cluster, at ~11% of revenue, grew ~11%, with Cuttack and Ranchi performing well and Kolkata expected to benefit from ongoing clinician onboarding.
• The transition is expected to normalize: Management stated the low-margin business transition should normalize over the next couple of quarters, and the medium-term revenue growth estimate remains close to 15%.

Mattoo: "the growth will happen through multiple levers, not just occupancy enhancement... there are many levers that are play at play here which will help us expand margin meaningfully over the next year."

Margin Trajectory & Profitability Levers

• FY26 margin walk: EBITDA margin improved 70 bps to 18.5%, driven by operating leverage, better utilization, throughput optimization, and disciplined cost management. Pre-tax ROCE improved to 14%.
• FY27 target is another 100 bps: Management expressed confidence in delivering an additional 100 bps of EBITDA margin expansion in FY27, citing opportunities across all clusters.
• Cluster margin profile: South, the mature cluster, already operates at 25%+ margins. West and East are seen as having more delta for expansion.
• Center utilization as a lever: Center utilization is a blended metric capturing chemo beds, OT utilization, and radiation machine utilization. Ahmedabad, at 50% center utilization, has significant headroom in a rapidly expanding market.
• Cost-side opportunities identified: Procurement and lease optimization are being targeted alongside revenue-quality improvements.
• Bucket migration explains margin dips: The apparent margin decline in the ₹5-10 crore and sub-₹5 crore revenue buckets reflects centers graduating to higher buckets, not underlying deterioration. Management sees scope to improve margins and ROCE in the sub-₹5 crore bucket in subsequent quarters.

Mattoo: "South is a mature cluster with margins already 25% plus. But we will we see opportunities for margin expansion all across."

Network Expansion: Beds, Centers & New Markets

• North Bangalore is live: A comprehensive oncology center opened with medical, surgical, and radiation oncology, nuclear medicine, PET-CT, BMT, and Bangalore's first MR-Linac, deployed on a pay-per-use, asset-light model. It is expected to be a big growth driver.
• 200+ brownfield beds in 24 months: Planned additions include Cuttack (+75), Ranchi (+30), Vizag (+50), and Bhavnagar (20+), at an average cost of ~₹45 lakh per bed, implying ~₹90-100 crore total capex.
• Whitefield relocation: Management is seeking an alternate location providing at least 120-130 beds to capture the market potential.
• Day-Care center push: 8-10 Day-Care centers will be added over the next 24 months across multiple markets, up from the current 5.
• Greenfield pipeline: At least 10-12 cities are under evaluation, including Pune, Surat, Coimbatore, Nellore, Lucknow, and Jalandhar, with locations finalized periodically based on market potential, location availability, and talent pipeline.
• 1,000 beds by FY30: The medium-term target is to add approximately 1,000 beds, split into 400 greenfield and 600 brownfield.
• Inorganic options being evaluated: Management confirmed inorganic growth options are under evaluation but had no major updates to share.

Milann Divestiture: Rationale & Terms

• A non-core asset with declining footprint: Milann's operating footprint shrank from 9 centers to 6 over HCG's 13-year ownership. The business operates at a low EBITDA margin, only marginally above break-even on a post-rent basis.
• Revival would have been a distraction: Turning Milann around would have required significant management bandwidth and primary capital infusion, both of which sit outside HCG's current strategic focus on its core oncology network.
• Transaction terms: The board approved the sale to Inviga Healthcare Fund at an enterprise valuation of ₹63 cr, with equity consideration of ₹37.6 cr, 75% upfront and 25% over 18 months. The deal was signed May 19, 2026, and is expected to close within Q1 FY27.
• Process was competitive: A comprehensive sale process was run, with Inviga shortlisted as the preferred buyer based on valuation maximization, transaction certainty, and a smooth transition for employees.

Mattoo: "Milanns operating footprint has, you know, steadily declined. The number of centers has come down from 9 to 6 and today the business operates at a low EBITDA margin and remains only marginally above break-even on a post-rent basis."

Balance Sheet, Capital Allocation & Returns

• Rights issue strengthens the balance sheet: ₹425 cr was raised with strong shareholder response, proceeds will be used to repay long-term debt, and some reduction in interest cost is expected going forward.
• Net debt-to-EBITDA ceiling at 2.5x: Management maintains an internal cap of 2.5x over the medium to long term.
• ROCE trajectory improving: Pre-tax ROCE reached 14% in FY26, supported by higher utilization, center maturity, and disciplined capital allocation. The company expects to hit 20% ROCE over the next four to five years.
• Cash conversion is healthy: Normalized for ESOP settlements, EBITDA-to-CFO conversion stands at 87%, with improvement expected going forward.
• Revenue per patient focus: Management emphasized that growth must be accompanied by margin expansion, better returns, improved quality of earnings, and stronger cash generation. The intentional reduction of lower-margin business supports this shift.

Clinical Differentiation & Competitive Position

• 35-year oncology moat: Management expressed confidence in HCG's clinical differentiation and the moat built over 35 years, stating the company is a leader in most markets it operates in.
• Clinical milestones in Q4: A rare robotic-assisted endoscopic urological procedure was published in an international journal; a complex dual primary malignancy case was managed; an ultra-personalized immuno-radiation strategy achieved tumor regression in a centenarian with advanced cancer; and cytoreductive surgery with HIPEC was deployed for complex ovarian cancer cases.
• Clinician additions continue: 23 oncologists were added in Q4 alone, and ongoing clinician onboarding in Kolkata is expected to benefit that market.
• Digital initiatives underway: The objective is to improve patient acquisition quality, strengthen conversion, enhance patient experience, and reduce dependence on external channels over time.

Mattoo: "I think we are very confident of our clinical differentiation and the moat that we have created over 35 years. We are leaders in most of the markets that we operate in."

Guidance & Commitments

Key Metrics